News & articles

June 20, 2013 Past MPN Research Foundation grantees Srdan Verstovsek and Ross Levine contributed to a paper recently published by the American Society of Hematology which reports on a study of PV and ET patients treated with pegylated interferon alpha-2a, commonly known as Pegasys. Click here for the abstract and to read the full study. Pegasys is… Read More »NEW DATA ON USE OF PEGASYS FOR POLYCYTHEMIA VERA AND ESSENTIAL THROMBOCYTHEMIA

7-1-2013 The MPN Research Foundation and the Leukemia & Lymphoma Society are proud to announce the winners of the second round of the MF Challenge grant program. Winners of these one year concept grants focusing on fibrosis and myelofibrosis are:  John Varga and Jonathan Licht (Northwestern University)  Golam Mohi (State University of New York)  Emmanuele… Read More »MF CHALLENGE GRANTS FOR 2013

July 3, 2013 Recently the MPN Forum launched a new quarterly journal focused on scientific medical advances. The idea behind The MPNforum Quarterly Journal (MQJ) is to provide hematologists and scientists a professional forum to talk with other physicians and interested patients in plain English about diagnosis and treatment of myeloproliferative neoplasms. The first issue features a… Read More »NEW MPN QUARTERLY JOURNAL LAUNCHED

A new study by Mayo Clinic, Boston University School of Public Health, and the pharmaceutical company Sanofi’s department of Global Evidence & Value Development has found the prevalence of MPN patients living in the United States to be much higher than previously assumed. They recently concluded a study which used two major insurance claims databases… Read More »NEW PREVALENCE DATA FOR MPNS

July 15, 2013 Recently the New England Journal of Medicine ran a letter to the editor drawing attention to a case in which an MF patient on Jakafi suffered an incidence of progressive multifocal leukoencephalopathy (PML) after starting therapy. Click here for full article Research is ongoing as to whether this is an isolated incident… Read More »NEJM LETTER RAISES CONCERN ABOUT PML AND JAKAFI

July 15, 2013 Emmanuelle Passegue (University of California, San Francisco) has recently published results of a study of the bone marrow niche. Her focus has been on the osteoblastic lineage cell derivatives. In this study they show that leukemic myeloid cells stimulate stromal cells, causing them to overproduce functionally altered osteoblastic cells, which then accumulate in… Read More »EMMANUELLE PASSEGUE PUBLISHES ON MF STUDY

May 2011 Beginning in 2010 the MPN Research Foundation began playing host to a gathering of MPN specialists in the Chicago area, recruiting doctors from RUSH, Northwestern, University of Chicago, University of Illinois at Chicago, and Loyola. This group, known now as the Chicago MPN Roundtable™, was conceptualized as a way to draw clinicians and… Read More »ANNOUNCING THE CHICAGO MPN ROUNDTABLE

August 2013 Incyte Corp. has announced two new trials that are currently recruiting ET and PV patients: Recruiting Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) Recruiting Switch Study From Hydroxyurea to Ruxolitinib for RELIEF of Polycythemia Vera Symptoms: The Relief Study According to representatives from Incyte,… Read More »NEW TRIAL RECRUITING PV AND ET PATIENTS

In 2010, The U.S. House of representatives declared September to be a time in which to raise awareness and support activities that will help people living with all types of blood cancer. In September the MPN community will have a unique opportunity to draw attention to polycythemia vera, essential thrombocythemia and myelofibrosis by celebrating national Blood… Read More »Take action this September to change your prognosis

September 3, 2013 by Andrew Schafer, MD, Scientific Advisory Board Chair and Chairman of Medicine, Weil Cornell Since 2000, the MPN Research Foundation has provided nearly $9 million in research funding to advance the treatment of the myeloproliferative neoplasms (essential thrombocythemia, polycythemia vera and myelofibrosis.) It is a modest amount relative to the magnitude of… Read More »MPN BCAM 2013: PATIENTS IN ACTION